Syros is advancing a robust clinical-stage pipeline that includes: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia (AML); SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; SY-5609, a highly selective and potent oral CDK7 inhibitorin patients with select solid tumors and blood cancers; and multiple preclinical and discovery programs . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post From Junk to Treasure: Syros Pharmaceuticals Mines Non-Coding DNA to Treat Disease appeared first on GEN – Genetic Engineering and Biotechnology News.
